• Medientyp: E-Artikel
  • Titel: NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
  • Beteiligte: Michelotti, Anna; de Scordilli, Marco; Bertoli, Elisa; De Carlo, Elisa; Del Conte, Alessandro; Bearz, Alessandra
  • Erschienen: MDPI AG, 2022
  • Erschienen in: International Journal of Molecular Sciences, 23 (2022) 12, Seite 6748
  • Sprache: Englisch
  • DOI: 10.3390/ijms23126748
  • ISSN: 1422-0067
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting.
  • Zugangsstatus: Freier Zugang